Impact of Minimally Invasive Surgery on Early and Late Outcomes of Patients With Gastric Cancer Treated Using Neoadjuvant Chemotherapy
- PMID: 39295557
- DOI: 10.1002/jso.27904
Impact of Minimally Invasive Surgery on Early and Late Outcomes of Patients With Gastric Cancer Treated Using Neoadjuvant Chemotherapy
Abstract
Background: Gastric cancer is the fifth most common neoplasm and the third leading cause of cancer-related death worldwide. Neoadjuvant chemotherapy is recommended for Stages II-III resectable tumors, but the comparative effectiveness of minimally invasive surgery (MIS) versus open gastrectomy (OG) post-neoadjuvant therapy has not been adequately investigated.
Methods: A retrospective cohort analysis was performed on patients with clinical Stage II and III gastric adenocarcinoma who underwent neoadjuvant chemotherapy followed by either MIS or OG between 2007 and 2020. Propensity score matching was utilized to compare the clinical and surgical outcomes, morbidity, and mortality, and the influence of MIS on 3-year survival rates was evaluated.
Results: After matching, no statistical differences in clinical aspects were noted between the two groups. MIS was associated with increased D2 lymphadenectomy, curative intent, and complete neoadjuvant therapy. Furthermore, this therapeutic approach resulted in reduced transfusion rates and shorter hospital stays. Nonetheless, no significant differences were observed in global, clinical, or surgical complications or mortality between the two groups. Weight loss emerged as a significant risk factor for complications, but MIS did not independently affect survival rates. Extended resection and higher American Society of Anesthesiology scores were independent predictors of reduced survival.
Conclusion: MIS after neoadjuvant chemotherapy for gastric cancer appears to be a viable option, with oncological outcomes comparable to those of OG, less blood loss, and shorter hospital stays. Although MIS did not independently affect long-term survival, it offered potential benefits in terms of postoperative recovery and morbidity. Further studies are needed to validate these findings, especially across diverse populations.
Keywords: gastric cancer; minimally invasive surgery; neoadjuvant chemotherapy; surgical outcomes.
© 2024 Wiley Periodicals LLC.
Similar articles
-
Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma.J Surg Oncol. 2020 Mar;121(3):486-493. doi: 10.1002/jso.25834. Epub 2020 Jan 9. J Surg Oncol. 2020. PMID: 31919862 Free PMC article.
-
The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.J Surg Oncol. 2025 Mar;131(3):417-426. doi: 10.1002/jso.27934. Epub 2024 Oct 13. J Surg Oncol. 2025. PMID: 39400342 Free PMC article.
-
Survival Outcomes Between Minimally Invasive and Open Gastrectomy in Early and Locally Advanced Gastric Adenocarcinoma in a Western Center.J Gastrointest Cancer. 2025 Feb 20;56(1):68. doi: 10.1007/s12029-024-01163-y. J Gastrointest Cancer. 2025. PMID: 39979489
-
Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?World J Gastroenterol. 2018 Jan 14;24(2):274-289. doi: 10.3748/wjg.v24.i2.274. World J Gastroenterol. 2018. PMID: 29375213 Free PMC article. Review.
-
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.Dig Surg. 2013;30(2):119-29. doi: 10.1159/000350877. Epub 2013 Jul 18. Dig Surg. 2013. PMID: 23867588 Review.
Cited by
-
Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis.BMC Gastroenterol. 2025 May 14;25(1):371. doi: 10.1186/s12876-025-03969-x. BMC Gastroenterol. 2025. PMID: 40369412 Free PMC article.
-
Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma.World J Gastroenterol. 2025 May 21;31(19):106644. doi: 10.3748/wjg.v31.i19.106644. World J Gastroenterol. 2025. PMID: 40497089 Free PMC article.
References
-
- A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians 61, no. 2 (March/April 2011): 69–90.
-
- R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer Statistics, 2014,” CA: A Cancer Journal for Clinicians 64, no. 1 (January/February 2014): 9–29.
-
- H. S. C. Ribeiro, Expressão proteica de PD‐L1 em pacientes com adenocarcinoma gástrico e de transição esôfago‐gástrica antes e após tratamento neoadjuvante e correlação com desfechos clínicos [Tese]. (São Paulo: Fundação Antônio Prudente, 2020).
-
- Japanese Gastric Cancer Association, Japanese Gastric Cancer Treatment Guidelines 2018 (5th ed),” Gastric Cancer 24 (2021): 1–21.
-
- L. C. Barchi, M. F. K. P. Ramos, A. R. Dias, et al., “Brazilian Gastric Cancer Association Guidelines: Update on Treatment,” Arquivos Brasileiros de Cirurgia Digestiva 34, no. 1 (2021): e1563.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous